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Abstract
Objective: Mitochondrial dysfunction is a hallmark of idiopathic Parkinson’s
disease (IPD), which has been reported not to be restricted to striatal neurons.
However, studies that analyzed mitochondrial function at the level of selected
enzymatic activities in peripheral tissues have produced conflicting data. We
considered the electron transport chain as a complex system with mitochondrial
membrane potential as an integrative indicator for mitochondrial fitness. Meth-
ods: Twenty-five IPD patients (nine females; mean disease duration, 6.2 years)
and 16 healthy age-matched controls (12 females) were recruited. Live platelets
were purified using magnetic-activated cell sorting (MACS) and single-cell data
on mitochondrial membrane potential (Δw) were measured by cytometry and
challenged with a protonophore agent. Results: Functional mitochondrial mem-
brane potential was detected in all participants. The challenge test reduced the
membrane potential in all IPD patients and controls (P < 0.001). However, the
response to the challenge was not significantly different between patients and
controls. Interpretation: While the reported protonophore challenge assay is a
valid marker of overall mitochondrial function in live platelets, intact mito-
chondrial membrane potential in platelets derived from IPD patients suggests
that presumed mitochondrial enzymatic deficiencies are compensable in this cell
type. In consequence, mitochondrial membrane potential in platelets cannot be
used as a diagnostic biomarker for nonstratified IPD but should be further
explored in potential Parkinson’s disease subtypes and tissues with higher
energy demands.
Introduction
In idiopathic Parkinson’s disease (IPD), cellular dysfunc-
tion is not limited to nigrostriatal cells. Mitochondrial
dysfunction has been described in both neurons and
non-neuronal cells.1 It could potentially serve as bio-
marker for early diagnosis and patient stratification.
However, translational studies on mitochondrial dysfunc-
tion are limited to readily available tissues such as blood
components. Direct brain tissue measurements are
excluded. Extensive reports have been published on PD-
associated mitochondrial dysfunction in platelets.2–6
These reports used biochemical in vitro methods to
compare the enzymatic activity of mitochondrial com-
plexes between patients and controls. However, in vivo
validation of these findings is missing and since the
early 1990s the findings of defects in platelet mitochon-
drial activity remain controversial and without clinical
application.
In this work, we investigate whether mitochondrial
membrane potential (Δw) in live platelets can be used
as a biomarker for IPD. In contrast to complex-specific
measurements of enzymatic activities, Δw provides
functional assessment of overall mitochondrial fitness.
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Methods
Subjects and clinical tests
The study was performed with written consent of all par-
ticipants and after approval by the Luxembourg National
Research Ethics Committee (CNER). Nondemented IPD
patients and healthy age-matched controls without clinical
evidence for neurodegenerative disorders were recruited
within a prospective study on mitochondrial dynamics.
IPD diagnosis was established following the London Brain
Bank criteria.7 All subjects underwent the following clini-
cal tests, with the patients being on their usual antipar-
kinsonian medication: the Hoehn and Yahr scale,8 the
motor part of the Unified Parkinson Disease Rating Scale
(UPDRSIII),9,10 and the Mini-Mental State Examination
(MMSE).11 Fresh whole blood was collected in EDTA
tubes and kept at room temperature. The samples were
annotated with an anonymous but traceable barcode.
Investigators performing downstream workflows such as
platelet purification and measurements of mitochondrial
membrane potential were blinded for the clinical identity
of the samples.
Purification of platelets
For the purification of platelets, 200 lL of CD61
microbeads (130-051-101; Miltenyi Biotec, Leiden, The
Netherlands) were mixed with 800 lL of EDTA blood
and incubated for 15 min at room temperature. The sam-
ples were diluted with 4 mL of 0.2 lm filtered platelet
buffer (PBS, 0.5% BSA, 2 mmol/L EDTA, pH 7.2) at
room temperature. Magnetic sorting was run on an Auto-
MACS (Miltenyi Biotec), using AutoMACS columns
(130-021-101; Miltenyi Biotec), running buffer (130-091-
221; Miltenyi Biotec), and washing buffer (130-092-987;
Miltenyi Biotec). The purified platelets were quantified on
a CASY cell counter (Roche Applied Science, Penzberg,
Germany), kept at room temperature, and prepared for
the analysis of mitochondrial membrane potential.
Mitochondrial staining and cytometry
Within the day of blood sampling mitochondrial mem-
brane potential (Δw) was analyzed by the nonquenching
TMRM method.12 One million platelets were collected in
4 mL DPBS (14190094; Invitrogen, Gent, Belgium) + 1%
FBS (10500064; Invitrogen). From this master mix, three
aliquots were prepared (3 9 1 mL): one unstained con-
trol, and two samples stained with 10 or 20 nmol/L
TMRM (T668; Invitrogen) as shown in the results. To
equilibrate the level of TMRM in platelets and mitochon-
dria,13 the cells were incubated for 45 min. To remove
potential cell clumps, the purified platelets were filtered
through a 40 lm filter (352340; BD Falcon, Erembode-
gem, Belgium) before starting the measurements. One of
the stained samples was used as a reference measurement
and the other one was used for an FCCP challenge test as
described in the next section. The intensity of TMRM flu-
orescence was measured via cytometry. Each data point
corresponds to the total TMRM signal of one platelet.
Cytometry measurements were performed using a BD
LSR Fortessa cytometer. The total number of events to be
measured for each sample was set to 10,000. Forward
scatter (FSC) and side scatter (SSC) signals were used to
gate the platelets by size and complexity, respectively. For
statistics the median forward scatter (MedFSC) and med-
ian side scatter (MedSSC) were used. TMRM fluorescence
was excited with a 561-nm laser and detected behind a
582/15 bandwidth filter.
Mitochondrial challenge
To dissipate mitochondrial membrane potential, cells
were treated with the protonophore FCCP. Challenge
with 5 lmol/L FCCP started after 45 min TMRM stain-
ing.
Statistical analysis
Single-cell data from cytometry were imported in fcs for-
mat to Matlab version R2013A (The MathWorks Inc.).14
The analysis of fluorescence intensity was restricted to
cells with defined size and complexity. To define coherent
boundaries for SSC and FSC, all data points of the study
were cumulated in a scatter plot and manually gated
using polygonal selection (Fig. 1).
To quantify the drop in TMRM fluorescence induced
by an FCCP challenge, we defined the following metric:
DDw ¼ 1 TMRM65
TMRM45
where TMRM45 is the median fluorescence intensity after
45 min of TMRM staining, minus the median back-
ground fluorescence in unstained samples at that time-
point. TMRM65 is the median fluorescence intensity after
additional 20 min of treatment with FCCP, minus the
median background fluorescence at that timepoint. Con-
sequently, ΔΔw corresponds to the FCCP-induced frac-
tional loss of TMRM fluorescence. Mitochondria with
high membrane potential present a higher ΔΔw than
mitochondria with low membrane potential. The ratio
normalizes against changes in total TMRM fluorescence.
To evaluate the impact of FCCP treatments on the level
of TMRM fluorescence in individual samples, the fluores-
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cence intensities of reference cell populations stained for
45 min with TMRM were compared to fluorescence levels
in cell populations which underwent a subsequent FCCP
challenge for 20 min. The two-sided Wilcoxon rank sum
test was used to test for equality of population medians.15
To test if the means of clinical- and cytometry-based
features are equal between patients and controls, two-
tailed two-sample Student t-tests, with a = 0.05, assuming
sampling from populations with equal variances, were
used.
Figure 1. Analysis of mitochondrial membrane potential in live platelets: Individual example data set: scatter plots highlight gated cells in blue
and the corresponding histograms show counts of gated cells at TMRM fluorescence intensity. The line plot at the bottom left shows the
dynamics of TMRM fluorescence in the given data set. The reference coordinates for the calculation of ΔΔw are highlighted in cyan and ΔΔw
which represents the fractional loss of TMRM fluorescence due to FCCP challenge is shown in black. The histogram at the bottom right shows
the cumulated count of study participants with given ΔΔw values. SSC, FCS, and TMRM fluorescence are shown in arbitrary units. TMRM,
tetramethylrhodamine, methyl ester; FCCP, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; SSC, side scatter.
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Correlations between pair-wise features including
cytometry-based data as well as clinical metadata were
calculated using the Pearson’s linear correlation coeffi-
cient (r). Correlations of the type 0.5 < |r| < 1 are con-
sidered as strong correlations, where |r| is the absolute
value of the coefficient of correlation.
Results
Twenty-five IPD patients (nine females; age: 55–80 years)
with IPD and 16 healthy controls (12 females; age: 60–
83 years) were recruited. Demographics and cytometry
data are presented in Table 1.
For the analysis of mitochondrial membrane potential,
the fractional loss of TMRM fluorescence after FCCP chal-
lenge (ΔΔw) was quantified. To evaluate the sensitivity of
the established ΔΔw assay for live platelets, both staining
efficiency and sensitivity for a loss in mitochondrial mem-
brane potential were analyzed. The consistently and signif-
icantly increased fluorescence of TMRM-stained platelets
compared to unstained cells, with P < 0.001 for each par-
ticipant, shows that MACS purified platelets are able to
take up TMRM and hence present internal negatively
charged compartments.13 The consistent and significant
drop of TMRM fluorescence after treatments with the pro-
tonophore FCCP, with P < 0.001 and 0.2 < ΔΔw < 0.8
for each study participant (Fig. 1), demonstrates the
presence of detectable levels of mitochondrial membrane
potential in all samples. Because treatment with 5 lmol/L
FCCP completely uncouples respiration, high ΔΔw val-
ues indicate a high original mitochondrial membrane
potential.
The results of FCCP challenge tests did not significantly
differ between patients and controls (Fig. 2). Platelets
from a first subcohort with 17 IPD patients and seven
controls have been analyzed with a 10 nmol/L-TMRM
protocol and no significant differences in ΔΔw were
found (Fig. 2). The negative skewness, a measure of dis-
tribution asymmetry, of 0.40 for patients and 0.39 for
controls shows that the distributions are stretched toward
low ΔΔw values and most individuals present a high
ΔΔw. To validate this result, platelets from a second
group of study participants including eight patients and
nine controls were analyzed with a 20 nmol/L-TMRM
protocol. Here, the absence of significant differences
between patients and controls was confirmed. The
skewness of 0.84 for patients and 0.50 for controls
confirms the distribution asymmetry with a tail toward
low ΔΔw and higher density at high ΔΔw (Fig. 2). The
controls were matched for age but not for gender
(Table 1). However, there was no significant difference in
ΔΔw between males and females (P = 0.51). Interestingly,
each subcohort presents an at least marginally stronger
skewness in patients than in controls. Of note, the two
participants with the lowest ΔΔw in each subcohort were
IPD patients (Fig. 2). The analysis of cell size and com-
plexity showed no significant differences between patients
and controls (Table 1).
The analysis of correlation within the whole study
cohort shows strong correlations between the size and
complexity of platelets, and, as expected, between disease
progression and the progression of motor phenotypes
(Hoehn Yahr and UPDRS). Strong negative correlations
were found between these disease progression features
Table 1. Demographics and cytometry data.
Parkinson’s disease Control P value
Demographics
Gender distribution (M:F) 25 (16:9) 16 (4:12) 0.025
Age 65.9  5.8 (55–80) 66.9  6.9 (60–83) 0.62
Clinical data
Hoehn Yahr 1.5  0.6 (1–2.5) 0  0 (0–0) 3.80E-13
UPDRSIII 12.0  6.1 (5–27) 0.9  1.3 (0–3) 1.27E-08
MMSE 28.6  1.4 (25–30) 28.9  1.5 (26–30) 0.54
Schwab England (%) 85  10% (60–100%) 100  0% (100–100%) 1.02E-06
Disease duration (years) 6.2  6.0 (1–25) NA NA
Cytometry data
Duration (min) 352  49 (257–446) 343  48 (276–438) 0.57
MedFSC 1787  238 (1446–2297) 1769  200 (1294–2107) 0.81
MedSSC 337  24 (300–398) 347  24 (298–391) 0.19
ΔΔw 0.63  0.14 (0.28–0.79) 0.65  0.13 (0.44–0.79) 0.58
The demographics on gender distribution are given in the format “participants (males: females).” The remaining statistics are presented in the
format “mean  standard deviation (minimum–maximum).” The P value for gender distribution was computed via Fisher’s exact test. All other P
values were calculated using Student t-tests. The duration in the cytometry section corresponds to the duration between blood sampling and
cytometry measurement. NA, not applicable; MedSSC, median side scatter; MedFSC, median forward scatter.
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and individual levels of independence (Schwab & Eng-
land). ΔΔw does not correlate strongly with any clinical
parameter (Fig. 3).
Discussion
Since the 1980s, mitochondrial dysfunction in platelets
has been vividly debated as a potential biomarker for
IPD.16–18 Parker et al. reported a 55% reduced complex I
activity in enriched mitochondria preparations from par-
kinsonian platelets.2 Benecke et al. concluded on a similar
downregulation of complex I activity by about 50%,5 via
the analysis of NADH oxidation, which is catalyzed by
complex I. Krige et al.3 who worked with a duration-opti-
mized protocol for the enrichment of platelet mitochon-
dria reported a 16% reduced activity of complex I in IPD
patients. Other authors did not find differences in com-
plex I activity between patients and controls by analyzing
platelet homogenates or platelets obtained by aphere-
sis.6,18 These contradictory results were probably due to
differences in sample preparation and analytical method-
ology. The quantification of enzymatic activity within the
electron transport chain was based on biochemical assays
requiring prior isolation of intact enzymes extracted from
blood, isolated platelets, or isolated platelet mitochondria.
Resulting differences in the level of platelet and enzyme
purity, and in the degree of enzymatic activity loss, due
to the use of different methods have a high impact on
obtained results. While the biochemical finding of
reduced complex I activity in platelets was reported in the
studies with the most efficient extraction methods for
functionally active enzymes,2–4 significance levels were not
reached with less sophisticated protocols.18,19
In comparison with former studies focusing on enzy-
matic activities, the present approach has several advanta-
ges: the cellular environment of the mitochondria is
maintained, the volume of the required blood samples is
reduced, and cytometric single-cell data are available.
Furthermore, MACS reduces the risk for inadvertently
induced platelet activation as it does not require sample
centrifugation such as apheresis. MACS also involves sev-
eral washing steps, separates the platelets from potential
blood-derived coagulation-promoting factors, and hence
further reduces the risk for platelet activation during cell
sorting. This centrifugation-free purification method pro-
vides sufficient amounts of intact platelets for the cytome-
try-based analysis of Δw. The reproducible response to
FCCP challenge tests both in patients and controls shows
that the MACS purified platelets carry active mitochon-
dria and that the introduced metric ΔΔw permits the
study of mitochondrial activity in live platelets. While
measurements of mitochondrial membrane potential in
live platelets have already been reported in the context of
a platelet activation study.20 A novelty of the present
study is the use of an FCCP challenge test in TMRM-
stained live platelets. This method allows to study the
dynamics of Δw under normalized conditions. Based on
Figure 2. Mitochondrial membrane potential in platelets is intact in
both, Parkinson’s disease patients and controls: The study cohort was
split in two groups. In a first group, platelets were stained with
10 nmol/L-TMRM (left plot) and no significant changes between
patients (red, P) and controls (blue, C) were found. In the second group
of participants (right plot), this result was validated using 20 nmol/L-
TMRM. The P values from two-sided Wilcoxon rank sum tests are
shown at the bottom of each plot. Furthermore, there were no
significant differences between the 10 and 20 nmol/L-TMRM
subcohorts (Ppatients = 0.28 and Pcontrols = 0.84). TMRM, tetramet-
hylrhodamine, methyl ester.
Figure 3. Analysis of correlation: no strong correlations were found
between ΔΔw and demographic-, clinical-, or cytometry-based
features. Coefficients of correlation (r) are color-coded according to
the colormap at the right.
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the findings presented above, our study demonstrates the
presence of intact mitochondrial membrane potential in
platelets from IPD patients and excludes quantitative
measurements of mitochondrial membrane potential in
live platelets as diagnostic biomarker for IPD in general.
However, different subtypes of IPD might still present
different levels of mitochondrial dysfunction. Thus, the
observation that those participants with the lowest ΔΔw
values have been IPD patients allows to speculate on a yet
undefined IPD subtype with an especially severe mito-
chondrial phenotype.
As our findings are at first look in contradiction with
previous findings on enzymatic defects in oxidative phos-
phorylation, compensatory mechanisms, able to re-estab-
lish intact Δw, have to be discussed. Reduced activity of
complex I could be compensated by an increased activity
of complex II.21 Compensation of complex I dysfunction
through increased activity in more distal complexes has
also been seen in OPA1-linked autosomal dominant optic
atrophy.21 Increased mitochondrial NADH levels could
also compensate complex I deficiency.22 Finally, it should
be emphasized that IPD patients lack any clinical signs
suggestive of platelet dysfunction, an observation well in
line with the present findings.
Cell types with higher energetic needs such as dopami-
nergic neurons of the substantia nigra might fail to com-
pensate mitochondrial deficits. First, it has been reported
that complex I and I + III activity in platelets does not cor-
relate with cerebral oxidative mitochondrial metabolism.23
Second, there are major physiological differences between
platelets and neuronal cell types, which are typically
affected in IPD. While both, platelets and neurons are post-
mitotic cells, platelets have a life expectancy of a week and
neurons a life expectancy comparable to the life expectancy
of humans. Energetic activity patterns are also different:
platelets are small cells with a diameter in the order of a few
micrometers, permitting only a few mitochondria per cell.
Increased energetic needs in platelets have been described
exclusively in the context of platelet activation,20 which has
been carefully avoided in the present setting. In contrast,
neurons affected in IPD have substantially higher energetic
needs. Cellular features requiring high energy demands
include the generation of autonomous action potentials,
poor myelination, and long and highly branched axons.24
Finally, the reported levels of complex I deficiency in sub-
stantia nigra outreach the reported levels of complex I defi-
ciency in platelets.16,18,25
The study has several limitations. We have recruited a
relatively small number of patients, mostly at a middle
stage of the disease. Thus, the observed difference in
skewness between patient and control groups might be
coincidental and we cannot exclude that significant
deficits in ΔΔw may be seen in more advanced stages of
the disease. All samples were derived from treated IPD
patients and a compensatory effect of the dopaminergic
treatment on ΔΔw integrity cannot be excluded. Further-
more, flow cytometry quantifies whole-cell fluorescence
(FWC), corresponding to the sum of mitochondrial fluo-
rescence (FM) and cytoplasmic fluorescence (FC). In cells
with polarized mitochondria, the ratio of FM/FC is very
high, at least in nonquenching mode, and therefore, FWC
is accepted as satisfactory surrogate for FM.
12 After release
from mitochondria TMRM rapidly redistributes across
the plasma membrane, especially in cells with a high
surface-to-volume ratio.12,26 The fluorescence remaining
after equilibration is in dependence of the plasma
membrane potential (Fig. 1). This cytoplasmic back-
ground according to the Nernst equation is perfectly
compatible with the ΔΔw method when assumed to be
constant. However, possible changes in plasma membrane
potential due to FCCP-induced effects including potential
shortage in ATP are ignored. The ceiling effect observed
in the ΔΔw histogram (Fig. 1) indicates that the dynamic
range of the assay corresponds to 80% of FWC. Filtering
during sample preparation could have removed very large
platelet clumps and thereby mask potential differences in
platelets that tend to clump. Finally, we did not evaluate
complex I deficits in study participants. In consequence,
the study cannot analyze the correlation between complex
I activity and mitochondrial membrane potential.
In summary, this study introduces a new easily applica-
ble and reproducible method to probe mitochondrial
membrane potential in live platelets. While the present
study excludes ΔΔw in platelets as a diagnostic biomarker
for IPD, it does not exclude the existence of IPD subtypes
with characteristic ΔΔw boundaries. Future applications
of the ΔΔw method in larger cohorts, possibly at a later
stage of the disease or before and during medication trials
should be envisioned. In order to gain full understanding
of the hypothesized cell type-specific mitochondrial
robustness in IPD, studies on other cell types such as fi-
broblasts and neurons derived from autonomic ganglia in
skin or colon are also needed.27
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